Table 2.
A comprehensive list of all the targeted toxins based on plant RIPs investigated so far.
| Toxin | Immunotoxin | Ligand | Target antigen | Tumor/Disease | In vitro | In vivo | Clinical trial status | Ref. |
|---|---|---|---|---|---|---|---|---|
| Abrin | Abrin-9.2.27 | mAb (9.2.27) | Melanoma-associated antigen (p250) | Melanoma | Yes | Yes | [279, 280] | |
| Abrin | Abrin-NR-ML-05 | mAb (NR-ML-05) | Melanoma-associated antigen (p250) | Melanoma | Yes | [281] | ||
| Abrin A-chain | Fib 75-abrin A chain | mAb (LICR-LOND Fib 75) | Bladder cancer antigen | EJ bladder cancer | Yes | Yes | [282-284] | |
| Abrin A-chain | C27-Abrin A chain (MAAC) | mAb (C27) | Carcinoembryonic antigen (CEA) | Colorectal cancer | Yes | Yes | [285] | |
| Abrin A-chain | Anti-Thy 1.1-Abrin A-chain | mAb (anti-Thy 1.1) (OX7) | CD90.1 (Thy 1.1) | AKR-A lymphoma | Yes | Yes | [286] | |
| Abrin A-chain | Anti-Hepatoma-associated Antigen-Abrin A-chain | mAb (anti-hepatoma-associated antigen L10 190 kDa glycoprotein) | Hepatoma-associated antigen L10 190 kDa glycoprotein | Hepatocarcinoma | Yes | [287] | ||
| Abrin A-chain | ITA | IgG (anti-Trypanosoma cruzi surface antigens) | Trypanosoma cruzi surface antigens | Trypanosoma cruzi | Yes | [288] | ||
| Abrin A-chain | F1G4-rABRa-A | mAb (F1G4) | Gonadotropin releasing hormone (GnRH) receptor | Breast cancer, hepatocarcinoma | Yes | [289] | ||
| Abrin A-chain | SWA11-SPDB-abrin A | mAb (SWA11) | CD24 | SCLC | Yes | [290] | ||
| Abrin A-chain | ABRaA-VEGF121 | VEGF121 | VEGFR-2 | Melanoma | Yes | Yes | [291] | |
| Abrin variant | Tfn-abrin variant | Human diferric transferrin (Tfn) | TfR | Glioblastoma multiforme, melanoma | Yes | [292] | ||
| Barley toxin I | H65-MM-rBRIP | mAb (H65) | CD5 | ALL | Yes | [293] | ||
| Barley toxin I | 4A2-MM-rBRIP | mAb (4A2) | CD7 | ALL | Yes | [293] | ||
| Barley toxin I | Anti-melanoma-BRIP | mAb (anti-melanoma) | Melanoma antigen | Melanoma | Yes | [294] | ||
| Barley toxin II | 5E9C11-Barley toxin II | mAb (HB21) (5E9) | TfR | Colon cancer | Yes | [157] | ||
| Bouganin | Anti-CD80/bouganin (M24-bouganin) | mAb (M24) | CD80 | Hodgkin's lymphoma, Burkitt's lymphoma | Yes | [295] | ||
| Bouganin | Anti-CD86/bouganin | mAb (anti-CD86) (1G10) | CD86 | Hodgkin's lymphoma, Burkitt's lymphoma | Yes | [295] | ||
| deBouganin | VB6-845 | Fab (4D5MOCB) | EpCAM | Solid tumors of epithelial origin | Yes | Yes | Phase I | [296, 297] |
| Bryodin-1 | OX7-bryodin | mAb (anti-Thy 1.1) (OX7) | CD90.1 (Thy 1.1) | AKR-A lymphoma | Yes | [298] | ||
| Bryodin-1 | BD1-G28-5 sFv | scFv (G28-5) | CD40 | B-cell non-Hodgkin’s lymphoma, multiple myeloma | Yes | [299, 300] | ||
| Bryodin-1 | chiBR96-BD-1 | scFv (BR96) | Ley antigen | Breast cancer | Yes | [301] | ||
| Bryodin-1 | Anti-epithelial antigen-bryodin | mAb (anti-epithelial antigen) | Epithelial antigen | Colon cancer, epidermoid carcinoma | Yes | [302] | ||
| Gelonin | Lym-I-gelonin | mAb (Lym-1) | HLA-DR | Burkitt’s lymphoma cells | Yes | [318] | ||
| Gelonin | B4G7-gelonin | mAb (B4G7) | EGFR | Lung cancer | Yes | Yes | [319] | |
| Gelonin | 80G-gelonin | mAb (80G) | Alpha-fetoprotein | Hepatoma | Yes | Yes | [320] | |
| Gelonin | ZME-gelonin | mAb (ZME-018) | Proteoglycan, p250 | Melanoma | Yes | Yes | [321, 322] | |
| Gelonin | Gelonin-9.2.27 | mAb (9.2.27) | Melanoma-associated antigen (p250) | Melanoma | Yes | Yes | [280] | |
| Gelonin | AChR-gelonin | AChR (nicotinic acetylcholine receptor) | IgG (anti-AChR) | Experimental autoimmune myasthenia gravis (EAMG) | Yes | Yes | [323] | |
| Gelonin | 38.13-gelonin | mAb (38.13) | TH ceramide (Pk antigen) | Burkitt's lymphoma | Yes | [324] | ||
| Gelonin | Anti-T11-gelonin | mAb (OKT11) | CD2 | T cells | Yes | Yes | [325, 326] | |
| Gelonin | Tf-gelonin | Transferrin | TfR | Malaria (Plasmodium falciparum) | Yes | [327] | ||
| Gelonin | AR3-gelonin | mAb (AR3) | CAR-3 | Gastric cancer | Yes | Yes | [328] | |
| Gelonin | 15A8-gelonin | mAb (15A8) | Breast cancer antigen | Breast cancer, cervical cancer | Yes | [329] | ||
| Gelonin | HB5-gelonin | mAb (HB5) | Cd3 receptor | EBV infection | Yes | [330] | ||
| Gelonin | Anti-Lyt 2.2-gelonin | mAb (anti-Lyt 2.2) (19/178C1) | Lyt2.2 | T-cell lymphoma | Yes | [331] | ||
| Gelonin | Anti-Thy 1.2-gelonin | mAb (anti-Thy 1.2) (AT15E) | CD90.2 (Thy 1.2) | T-cell lymphoma | Yes | [331] | ||
| Gelonin | Anti-Thy 1-gelonin | mAb (anti-Thy 1) (M549) | CD90 (Thy 1.1 and 1.2) | Leukemia | Yes | Yes | [332] | |
| Gelonin | LG 2/72-gelonin | mAb (LG 2/72) | HLA-DR | Lymphoma | Yes | [331] | ||
| Gelonin | Anti-MCMV-gelonin | IgG (anti-MCMV) | MCMV antigen (murine cytomegalovirus antigen) | CMV infection | Yes | [333] | ||
| Gelonin | Anti-HCMV-gelonin | IgG (anti-HCMV) | HCMV antigen (human cytomegalovirus antigen) | CMV infection | Yes | [333] | ||
| Gelonin | Anti-JL1-gelonin | mAb (anti-JL1) | JL1 | Leukemia | Yes | [334] | ||
| Gelonin | oLH-gelonin (lutropin-SS-gelonin) | Ovine luteinizing hormone (oLH) | Ovine LH receptor | Leydig cell tumor (testicular cancer) | Yes | [335] | ||
| Gelonin | hCG-gelonin | Human chorionic gonadotropin (hCG) | LH receptor | Leydig cell tumor (testicular cancer) | Yes | [335] | ||
| Gelonin | Gelonin-gp330 | gp330 (renal brush border antigen) | Anti-gp330 Ig | Heymann's nephritis | Yes | Yes | [336] | |
| Gelonin | Anti-PCV-gelonin | IgG (anti-PCV) | Pichinde virus (PCV) | Pichinde virus (PCV) | Yes | [337] | ||
| Gelonin | PC4.9A6-gelonin | mAb (PC4.9A6) | Pichinde virus (PCV) | Pichinde virus (PCV) | Yes | [337] | ||
| Gelonin | 14G2a-gelonin | mAb (14G2a) | Disialoganglioside GD2 | Neuroblastoma, melanoma | Yes | [338] | ||
| Gelonin | MSN-1-gelonin | mAb (MSN-1) | Endometrial adenocarcinoma antigen | Endometrial adenocarcinoma | Yes | Yes | [339] | |
| Gelonin | F(ab')2-gelonin/UCHT1 | F(ab')2 (anti-IgG) / mAb (UCHT1) | CD3 | T-cell lymphoma | Yes | [303] | ||
| Gelonin | H65-gelonin | mAb (H65) | CD5 | T-cell ALL | Yes | Yes | [340] | |
| Gelonin | BACH-250/rGel | mAb (BACH-250) | HER2 | Breast cancer | Yes | Yes | [341] | |
| Gelonin | TAB-250/rGel | mAb (TAB-250) | HER2 | Breast cancer | Yes | Yes | [341] | |
| Gelonin | VEGF121/rGel | VEGF121 | KDR Flk-1 receptor | Tumor neovasculature, melanoma, prostate cancer | Yes | Yes | [342] | |
| Gelonin | HuM195/rGel | mAb (HuM-195) | CD33 | AML, CML, myelodysplastic syndrome | Yes | Yes | Phase I | [343-346] |
| Gelonin | MEL scFv-rGel | scFv (MEL) | gp240 | Melanoma, brain cancer, lobular breast cancer | Yes | Yes | [347] | |
| Gelonin | BLyS-gelonin | B lymphocyte stimulator (BLyS) | BR3/BAFF-R, TACI and BCMA | B-NHL subtypes mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), B-cell precursor-acute lymphocytic leukemia (BCP-ALL) | Yes | Yes | [348-350] | |
| Gelonin | C6.5-rGel | scFv (C6.5) | HER2 | Breast cancer, gastric cancer, lung cancer, ovarian cancer | Yes | Yes | [351] | |
| Gelonin | e23-L-rGel | scFv (e23) | HER2 | Breast cancer, gastric cancer, lung cancer, ovarian cancer | Yes | [352] | ||
| Gelonin | ML3-9-rGel | scFv (ML3-9) | HER2 | Breast cancer, gastric cancer, lung cancer | Yes | Yes | [351] | |
| Gelonin | MH3-B1-rGel | scFv (MH3-B1) | HER2 | Breast cancer, gastric cancer, lung cancer | Yes | Yes | [351] | |
| Gelonin | B1D3-rGel | scFv (B1D3) | HER2 | Breast cancer, gastric cancer, lung cancer | Yes | Yes | [351] | |
| Gelonin | 3ErGel | scFv (sm3E) | Carcinoembryonic antigen (CEA) | Colorectal cancer | Yes | [353] | ||
| Gelonin | FErGel | scFv (shMFE) | Carcinoembryonic antigen (CEA) | Colorectal cancer | Yes | [353] | ||
| Gelonin | C7rGel | FN3 fragment (C743) | Carcinoembryonic antigen (CEA) | Colorectal cancer | Yes | Yes | [353, 354] | |
| Gelonin | E4rGel | FN3 fragment (E246) | EGFR | Colorectal cancer | Yes | Yes | [353, 354] | |
| Gelonin | 3C/rGel | scFv (3C) | FGFR3 | Multiple myeloma, hepatocellular carcinoma, bladder cancer | Yes | Yes | [355, 356] | |
| Gelonin | 7D/rGel | scFv (7D) | FGFR3 | Multiple myeloma, hepatocellular carcinoma, bladder cancer | Yes | Yes | [355] | |
| Gelonin | H45-rGeloninD274C | mAb (H45) | CD5 | ALL | Yes | Yes | [357] | |
| Gelonin | MOC31-gelonin | mAb (MOC31) | Epithelial glycoprotein-2 (EGP-2) | SCLC, colon cancer, breast cancer | Yes | [358] | ||
| Luffa ribosomal inhibitory protein (LRIP) | HB21-LRIP | mAb (HB21) (5E9) | TfR | T lymphoblastic leukemia | Yes | [168] | ||
| Luffin-A | Luffin A-Ng76 | mAb (Ng76) | Melanoma antigen | Melanoma | Yes | [359] | ||
| Luffin-B | Luffin B-Ng76 | mAb (Ng76) | Melanoma antigen | Melanoma | Yes | [360] | ||
| Luffin-B | LKP (Luffin-β-KDEL-uPAcs) | uPAcs (urokinase-type plasminogen activator) | Urokinase receptor | Non-small cell lung cancer (NSCLC) | Yes | [361] | ||
| Luffin-P1 | hIL-2-Luffin P1 | IL-2 | CD25 (IL-2 receptor) | Activated lymphocytes | Yes | Yes | [362-364] | |
| Luffin-P1 | EBI3-Luffin P1 | EBI3 (Epstein-Barr virus (EBV)-induced gene 3) | CD25 (IL-2 receptor) | Immunological diseases, erythroleukemia | Yes | [365] | ||
| Mistletoe lectin I A-chain |
Anti-CD5/MLIA | mAb (anti-CD5) | CD5 | T-lymphocytes | Yes | [366] | ||
| Mistletoe lectin I A-chain |
Anti-CD25/MLIA (Anti-CD25-MLA) | mAb (anti-CD25) | CD25 (IL-2 receptor) | Activated lymphocytes | Yes | [367] | ||
| Mistletoe lectin I A-chain |
MoAb-16-MLIA | mAb (16) | Oncofetal antigen | Leukemia | Yes | [368] | ||
| Mistletoe lectin I A-chain |
BMAC1/MLA | mAb (BMCA1) | CD45 | Allograft rejection | Yes | [369] | ||
| Mistletoe lectin I A-chain |
OX1/MLA | mAb (OX1) | rat CD45 | Allograft rejection | Yes | [369] | ||
| Momorcochin | Anti-epithelial antigen-momorcochin | mAb (anti-epithelial antigen) | Epithelial antigen | Colon cancer, epidermoid carcinoma | Yes | [302] | ||
| Momorcochin | F(ab')2-momorcochin/UCHT1 | F(ab')2 (anti-IgG) / mAb (UCHT1) | CD3 | T-cell lymphoma | Yes | [303] | ||
| Momorcochin-S | Momorcochin-S-A8 | mAb (8A) | 8A myeloma antigen | Burkitt lymphoma | Yes | Yes | [193] | |
| Momordin | OX7-momordin | mAb (anti-Thy 1.1) (OX7) | CD90.1 (Thy 1.1) | AKR-A lymphoma | Yes | [298] | ||
| Momordin | Fib 75-momordin | mAb (LICR-LOND Fib 75) | Bladder cancer antigen | EJ bladder cancer | Yes | Yes | [284, 312] | |
| Bryodin-1 | F(ab')2-bryodin/UCHT1 | F(ab')2 (anti-IgG) / mAb (UCHT1) | CD3 | T-cell lymphoma | Yes | [303] | ||
| Bryodin-2 | chiBR96-BD-2 | scFv (BR96) | Ley antigen | Breast cancer | Yes | [301] | ||
| Bryodin-2 | HB21-bryodin-II | mAb (HB21) (5E9) | TfR | Breast cancer | Yes | [304] | ||
| Colocin 1 | Anti-epithelial antigen-colocin 1 | mAb (anti-epithelial antigen) | Epithelial antigen | Colon cancer, epidermoid carcinoma | Yes | [302] | ||
| Curcin | Curcin-TfRBP9 | TfRBP9 [transferrin receptor (TfR) binding peptide] | TfR | Hepatocellular carcinoma | Yes | [305] | ||
| Dianthin 30 | BerH2-dianthin | mAb (Ber-H2) | CD30 | Lymphoblastoid, Hodgkin's lymphoma | Yes | [306, 307] | ||
| Dianthin 30 | Dianthin-EGF | EGF | EGFR | EGFR overexpressing cells | Yes | [84, 308] | ||
| Dianthin 30 | Tfn-dianthin | Transferrin | TfR | T-cell leukemia | Yes | [309] | ||
| Dianthin 32 | F(ab')2-dianthin 32/UCHT1 | F(ab')2 (anti-IgG) / mAb (UCHT1) | CD3 | T-cell lymphoma | Yes | [303] | ||
| Ebulin l | Ebulin l-transferrin | Transferrin | TfR | TfR-over-expressing cancer cells | Yes | [310] | ||
| Ebulin l | 44G4-ebulin | mAb (44G4) | CD105 (endoglin) | Tumor neovasculature | Yes | [311] | ||
| Gelonin | Fib 75-gelonin | mAb (LICR-LOND Fib 75) | Bladder cancer antigen | EJ bladder cancer | Yes | Yes | [284, 312] | |
| Gelonin | Anti-CD86/gelonin (αCD86-gelonin) | mAb (anti-CD86) (1G10) | CD86 | Hodgkin's lymphoma, Burkitt's lymphoma | Yes | Yes | [295, 313] | |
| Gelonin | Anti-CD80/gelonin (M24-gelonin) | mAb (M24) | CD80 | Hodgkin's lymphoma, Burkitt's lymphoma | Yes | [295] | ||
| Gelonin | αCD80-gelonin | mAb (B5B) | CD80 | Hodgkin's lymphoma, Burkitt's lymphoma | Yes | [313] | ||
| Gelonin | J5/gelonin | mAb (J5) | CD10 (CALLA) | Lymphoma | Yes | [314] | ||
| Gelonin | I-2/gelonin | mAb (I-2) | Ia antigen | Lymphoma | Yes | [314] | ||
| Gelonin | J30/gelonin | mAb (J30) | gp26 cell surface glycoprotein | Lymphoma | Yes | [314] | ||
| Gelonin | BerH2-gelonin | mAb (Ber-H2) | CD30 | Hodgkin's lymphoma | Yes | [307] | ||
| Gelonin | NDA4-gelonin | mAb (NDA4) | NDA4 antigen | EBV-transformed lymphoblastoid, gibbon MLA leukemia | Yes | [315] | ||
| Gelonin | HB21-gelonin (5E9-gelonin) | mAb (HB21) (5E9) | TfR | Colon cancer, Burkitt's lymphoma | Yes | Yes | [157, 316] | |
| Gelonin | OKT9-gelonin | mAb (OKT9) | TfR | Cervical cancer | Yes | [317] | ||
| Momordin | OM124-momordin | mAb (anti-CD22) (OM124) | CD22 | Burkitt's B-cell lymphoma, Epstein-Barr virus-infected B lymphoblastoid cells | Yes | Yes | [370] | |
| Momordin | 8A-Momordin | mAb (8A) | 8A myeloma antigen | Multiple myeloma | Yes | [371] | ||
| Momordin | Anti-CD5-Momordin | mAb (anti-CD5) | CD5 | T-cell leukemia | Yes | Yes | [372] | |
| Momordin | Anti-CD30-Momordin (Ber-H2-Momordin) | mAb (Ber-H2) | CD30 | Hodgkin's lymphoma, anaplastic large-cell lymphoma(ALCL) | Yes | Yes | [307, 373, 374] | |
| Momordin | BDI-1-momordin | mAb (BDI-1) | Bladder cancer antigen | Bladder cancer | Yes | Yes | Phase I | [375, 376] |
| Momordin | Folate-momordin | Folate | Folate receptor | Cervical cancer, ovarian cancer | Yes | [377, 378] | ||
| Momordin | Anti-epithelial antigen-momordin | mAb (anti-epithelial antigen) | Epithelial antigen | Colon cancer, epidermoid carcinoma | Yes | [302] | ||
| Momordin | F(ab')2-momordin/UCHT1 | F(ab')2 (anti-IgG) / mAb (UCHT1) | CD3 | T-cell lymphoma | Yes | [303] | ||
| Momordin I | 48-127/momordin I | mAb (48-127) | gp54 | Bladder cancer | Yes | [379] | ||
| Moschatin | Moschatin-Ng76 | mAb (Ng76) | Melanoma antigen | Melanoma | Yes | [380] | ||
| Nigrin b | 44G4-nigrin b | mAb (44G4) | CD105 (endoglin) | Tumor neovasculature | Yes | [381] | ||
| Nigrin b | MJ7-Ngb | mAb (MJ7/18) | CD105 (endoglin) | Tumor neovasculature, melanoma | Yes | Yes | [382, 383] | |
| Nigrin b | Nigrin b-transferrin | Transferrin | TfR | TfR-over-expressing cancer cells | Yes | [310] | ||
| Ocymoidine | Mint-Ocy | mAb (Mint5) | EGFR | Breast cancer | Yes | Yes | [384] | |
| PAP | B43-PAP | mAb (B43) | CD19 | Leukemia, B-cell ALL | Yes | Yes | Phase I | [385-388] |
| PAP | TXU-PAP | mAb (TXU) | CD7 | T-NHL, HIV type I | Yes | Yes | Phase I | [389-391] |
| PAP | Anti-Thy 1.1 (mAb)-PAP | mAb (anti-Thy 1.1) (OX7) | CD90.1 (Thy 1.1) | Leukemia | Yes | [392] | ||
| PAP | Anti-Thy 1.1 (F(ab')2)-PAP | F(ab')2 (anti-Thy 1.1) (OX7) | CD90.1 (Thy 1.1) | Leukemia | Yes | [392] | ||
| PAP | GnRH-PAP | Gonadotropinreleasing hormone (GnRH) | GnRH receptor | Breast cancer | Yes | [393, 394] | ||
| PAP | TP3-PAP | mAb (TP3) | p80 | Osteosarcoma | Yes | Yes | [395] | |
| PAP | J3-109-PAP | mAb (J3-109) | CD72 | B-cell ALL | Yes | [396] | ||
| PAP | 74-12-4-PAP | mAb (74-12-4) | porcine CD4 | Transplants | Yes | [397] | ||
| PAP | Anti-CD4-PAP | mAb (MT151) | CD4 | HIV | Yes | [398] | ||
| PAP | PAP-9.2.27 | mAb (9.2.27) | Melanoma-associated antigen (p250) | Melanoma | Yes | Yes | [280, 399] | |
| PAP | J5/PAP | mAb (J5) | CD10 (CALLA) | Lymphoma | Yes | [314] | ||
| PAP9 (High expressed mutated PAP) | PAP9-IL-2 | IL-2 | CD25 (IL-2 receptor) | T-cell lymphoma | Yes | [400] | ||
| PAP II | J5/PAP II | mAb (J5) | CD10 (CALLA) | Lymphoma | Yes | [314] | ||
| PAP-S | OM124-PAP-S | mAb (anti-CD22) (OM124) | CD22 | Burkitt's B-cell lymphoma, Epstein-Barr virus-infected B lymphoblastoid cells, Hodgkin's lymphoma | Yes | Yes | [307, 370] | |
| PAP-S | Anti-CD30-PAP-S (Ber-H2-PAP-S) | mAb (Ber-H2) | CD30 | Hodgkin's lymphoma, anaplastic large-cell lymphoma(ALCL) | Yes | Yes | [373, 401] | |
| PAP-S | 48-127/PAP-S | mAb (48-127) | gp54 | Bladder cancer | Yes | [379] | ||
| PAP-S | Anti-epithelial antigen-PAP-S | mAb (anti-epithelial antigen) | Epithelial antigen | Colon cancer, epidermoid carcinoma | Yes | [302] | ||
| PAP-S | F(ab')2-PAP-S/UCHT1 | F(ab')2 (anti-IgG) / mAb (UCHT1) | CD3 | T-cell lymphoma | Yes | [303] | ||
| PAP-S | J5/PAP-S | mAb (J5) | CD10 (CALLA) | Lymphoma | Yes | [314] | ||
| PD-S2 | Ber-H2-PD-S2 | mAb (Ber-H2) | CD30 | Hodgkin's lymphoma | Yes | [307] | ||
| Pyramidatine | Mint-Pyra | mAb (Mint5) | EGFR | Breast cancer | Yes | Yes | [384] | |
| Ricin | Anti-Ly2.1-ricin | mAb (anti-Ly2.1) | Murine T-cell antigen | T-cell ALL | Yes | Yes | [402] | |
| Ricin | Anti-CD8-ricin | mAb (B9.4.2) | CD8 | PBMCs | Yes | [403] | ||
| Ricin | Anti-CD4-ricin | mAb (HP2/6) | CD4 | PBMCs | Yes | [403] | ||
| Ricin | Anti-CD3-ricin | mAb (SPV-T3b) | CD3 | PBMCs | Yes | [403] | ||
| Ricin | Anti-CD3-ricin | mAb (11D8) | CD3 | PBMCs | Yes | [403] | ||
| Ricin | UCHT1-ricin | mAb (UCHT1) | CD3ε | GVHD | Yes | [404] | ||
| Ricin | 35.1-ricin | mAb (35.1) | CD2 | GVHD | Yes | [404] | ||
| Ricin | T101-ricin | mAb (T101) | CD5 | GVHD | Yes | Yes | [404, 405] | |
| Ricin | Ricin-HB55 | mAb (BH55) | HLA-DR | B-cell leukemia, lymphoma | Yes | [406] | ||
| Ricin | IL2-lectin-deficient RTB-RTA | IL-2 | CD25 (IL-2 receptor) | Leukemia | Yes | [407] | ||
| Ricin | GMCSF-ricin | GMCSF | GMCSF receptor | AML | Yes | [408] | ||
| Ricin | M6-ricin | mAb (M6) | L2C IgM idiotype | B-cell leukemia | Yes | Yes | [409] | |
| Ricin | Anti-GE2-ricin | mAb (anti-GE2) | GE2 | Glioma | Yes | [410] | ||
| Ricin | AR3-ricin | mAb (AR3) | CAR-3 | Gastric cancer, colorectal cancer | Yes | [411] | ||
| Ricin | BDI-1-ricin | mAb (BDI-1) | Bladder cancer antigen | Bladder cancer | Yes | [412] | ||
| Ricin | Ricin-mAb 35 | mAb (35) | AChR (nicotinic acetylcholine receptor) | Strabismus | Yes | Yes | [413, 414] | |
| Ricin | Anti-Lyt 2.2-ricin | mAb (anti-Lyt 2.2) (19/178C1) | Lyt2.2 | T-cell lymphoma | Yes | [331] | ||
| Ricin | IgE-intact ricin | mAb (IR162) | IgE Fc receptor | Allergies, basophil leukemia | Yes | [415] | ||
| Ricin | L6-ricin | mAb (L6) | Lung canger antigen | Lung cancer | Yes | Yes | [416] | |
| Ricin | Ricin-EGF | EGF | EGFR | Epidermoid carcinoma | Yes | [417] | ||
| Ricin | Anti-CD6-bR | mAb (anti-CD6) | CD6 | CTCL, ALL | Yes | Yes | Phase I | [418, 419] |
| Ricin | Anti-B4-bR | mAb (anti-B4) | CD19 | B-NHL | Yes | Yes | Phase III | [420-425] |
| Ricin | Anti-My9-bR | mAb (anti-My9) | CD33 | AML | Yes | Yes | Phase I | [418, 426, 427] |
| Ricin | N901-bR | mAb (N901) | CD56 (N-CAM) | SCLC | Yes | Yes | Phase II | [418, 428-431] |
| Ricin | Anti-CEA-bR | mAb (I-1) | Carcinoembryonic antigen (CEA) | Colorectal cancer | Yes | Yes | Phase I/II | [432] |
| Ricin | IF7-bR | mAb (IF7) | CD26 | T cells | Yes | [433] | ||
| Ricin | 4B4-bR | mAb (4B4) | CD29 | Lymphocytes, endothelium | Yes | [304] | ||
| Ricin | MT151-blocked ricin | mAb (MT151) | CD4 | ALL | Yes | [434] | ||
| Ricin | Anti-CD4.CD26-bRicin | Bispecific mAb (anti-CD4 x CD26) | CD4 + CD26 | GVHD | Yes | [433] | ||
| Ricin | Anti-CD4-bRicin | Fab' (19thy5D7) | CD4 | GVHD | Yes | [433] | ||
| Ricin | Anti-CD26-bRicin | Fab' (1F7) | CD26 | GVHD | Yes | [433] | ||
| Ricin | Anti-CD4.CD29-bRicin | Bispecific mAb (anti-CD4 x CD29) | CD4 + CD29 | Tissue allografts | Yes | [435] | ||
| Ricin | SEN31-bR | mAb (SEN31) | Cluster-5a antigen | SCLC | Yes | Yes | [436] | |
| Ricin | HB7-blocked ricin | mAb (HB7) | CD38 | Multiple myeloma, lymphoma | Yes | [437] | ||
| RTA | Anti-Thy 1.1-dgRTA | mAb (anti-Thy 1.1) (OX7) | CD90.1 (Thy 1.1) | AKR-A lymphoma | Yes | Yes | [438] | |
| RTA | Anti-CD7-dgA (DA7) | mAb (3A1e) | CD7 | T-NHL, leukemia, GVHD | Yes | Yes | Phase I | [439] |
| RTA | HD37-dgA (IMTOX-19) | mAb (HD37) | CD19 | B-NHL, ALL | Yes | Yes | Phase I | [440, 441] |
| RTA | RFB4-Fab'-dgA | Fab’ (RFB4) | CD22 | B-NHL, leukemia, lymphoma | Yes | Yes | Phase I | [442, 443] |
| RTA | RFT5-dgA (IMTOX-25) | mAb (RFT5) | CD25 | Hodgkin's lymphoma, CTCL, melanoma, GVHD | Yes | Yes | Phase II | [444-448] |
| RTA | Ki-4.dgA | mAb (Ki-4) | CD30 | Hodgkin's lymphoma, NHL | Yes | Yes | Phase I | [447, 449, 450] |
| RTA | RFB4-dgA (IMTOX-22) | mAb (RFB4) | CD22 | B-NHL, CLL, ALL, leukemia, lymphoma, myeloma | Yes | Yes | Phase I | [443, 451, 452] |
| RTA | Combotox (RFB4-dgA / HD37-dgA) | mAb (RFB4) + mAb (HD37) | CD22, CD19 | NHL, ALL | Yes | Yes | Phase I | [453, 454] |
| RTA | SPV-T3a-dgA + WT1-dgA | mAb (SPV-T3a) + mAb (WT1) | CD3, CD7 | GVHD | Yes | Yes | Phase I/II | [455, 456] |
| RTA | 3A1e-dgRTA | scFv (3A1e) | CD7 | T-cell leukemia | Yes | [457] | ||
| RTA | 3AIf-dgRTA | scFv (3A1f) | CD7 | T-cell leukemia | Yes | [457] | ||
| RTA | UV3-dgRTA | mAb (UV3) | CD54 (ICAM-1) | Myeloma, grnulocytes, monocytes | Yes | [458] | ||
| RTA | H22-dgRTA (CD64-RiA) | mAb (H22) | CD64 | AML, rheumatoid arthritis, monocytes, macrophages | Yes | Yes | [459-461] | |
| RTA | D5-dgA | mAb (D5) | Cytomegalovirus | Cytomegalovirus (MCMV) | Yes | [462] | ||
| RTA | C34-dgA | mAb (C34) | Cytomegalovirus | Cytomegalovirus (MCMV) | Yes | [462] | ||
| RTA | HMS-dgA | IgG (HMS) | Cytomegalovirus | Cytomegalovirus (MCMV) | Yes | [462] | ||
| RTA | 64.1-dgRTA | mAb (64.1) | CD3 | Lymphoproliferative disease (LPD) | Yes | Yes | [463, 464] | |
| RTA | HD6-dgA | mAb (HD6) | CD22 | Leukemia, lymphoma | Yes | [443] | ||
| RTA | HD6-Fab'-dgA | Fab’ (HD6) | CD22 | Leukemia, lymphoma | Yes | [443] | ||
| RTA | UV22-1-dgA | mAb (UV22-1) | CD22 | Leukemia, lymphoma | Yes | [443] | ||
| RTA | UV22-1-Fab'-dgA | Fab’ (UV22-1) | CD22 | Leukemia, lymphoma | Yes | [443] | ||
| RTA | UV22-2-dgA | mAb (UV22-2) | CD22 | Leukemia, lymphoma | Yes | [443] | ||
| RTA | UV22-2-Fab'-dgA | Fab’ (UV22-2) | CD22 | Leukemia, lymphoma | Yes | [443] | ||
| RTA | p67.7-dgA | mAb (p67.7) | CD33 | AML | Yes | [465] | ||
| RTA | 120-2A3-dgA | mAb (120-2A3) | TfR | Myeloma, Hodgkin's lymphoma | Yes | [465] | ||
| RTA | B-B10-dgA | mAb (B-B10) | CD25 (IL-2 receptor) | Myeloma, Hodgkin's lymphoma | Yes | [465] | ||
| RTA | TDR31-1-dgA | mAb (TDR31-1) | MHC class II | Myeloma, Hodgkin's lymphoma | Yes | [465] | ||
| RTA | SWA11-dg.RTA | mAb (SWA11) | CD24 | SCLC | Yes | Yes | [466, 467] | |
| RTA | M5/114-dgA | mAb (M5/114) | MCH Class II antigens (I-Ad, I-Ed) | Endothelial cells | Yes | Yes | [468] | |
| RTA | 11-4.1-dgA | mAb (11-4.1) | MCH Class I antigen (H-2Kk) | Neuroblastoma | Yes | Yes | [468, 469] | |
| RTA | E6-dgA | mAb (E6) | Prostate-specific membrane antigen (PSMA) | Prostate cancer | Yes | Yes | [470] | |
| RTA | 14G2a.dgA | mAb (14G2a) | Disialoganglioside GD2 | Neuroblastoma | Yes | Yes | [471] | |
| RTA | ch14.18.dgA | mAb (ch14.18) | Disialoganglioside | Neuroblastoma | Yes | [471] | ||
| RTA | BW704.dgA | mAb (BW704) | Disialoganglioside | Neuroblastoma | Yes | [471] | ||
| RTA | chCE7.dgA | mAb (chCE7) | 190 kDa Glycoprotein (gp190) | Neuroblastoma | Yes | [471] | ||
| RTA | FVS191cys-dgRTA | scFv (FVS191) | CD19 | Leukemia | Yes | [472] | ||
| RTA | K4-2C10-dgRA | mAb (K4-2C10) | CD105 (endoglin) | Tumor neovasculature, breast cancer | Yes | Yes | [473] | |
| RTA | SN6j-dgRA | mAb (SN6j) | CD105 (endoglin) | Tumor neovasculature, breast cancer | Yes | Yes | [474] | |
| RTA | SN6k-dgRA | mAb (SN6k) | CD105 (endoglin) | Tumor neovasculature, breast cancer | Yes | Yes | [474] | |
| RTA | D5-dgA | mAb (D5) | MCMV antigen (murine cytomegalovirus antigen) | CMV infection | Yes | Yes | [462, 475] | |
| RTA | C34-dgA | mAb (C34) | MCMV antigen (murine cytomegalovirus antigen) | CMV infection | Yes | Yes | [462, 475] | |
| RTA | FF1-4D5-dgA | mAb (FF1-4D5) | mouse δ H chain of surface IgD (mδsIgD), domain Fd | B-cells | Yes | [476] | ||
| RTA | AMS-15.1-dgA | mAb (AMS-15.1) | mouse δ H chain of surface IgD (mδsIgD), domain Fd | B-cells | Yes | [476] | ||
| RTA | 11-26-dgA | mAb (11-26) | mouse δ H chain of surface IgD (mδsIgD), domain Fd | B-cells | Yes | [476] | ||
| RTA | JA12.5-dgA | mAb (JA12.5) | mouse δ H chain of surface IgD (mδsIgD), domain Fd | B-cells | Yes | [476] | ||
| RTA | AMS-9.1-dgA | mAb (AMS-9.1) | mouse δ H chain of surface IgD (mδsIgD), domain Fc | B-cells | Yes | [476] | ||
| RTA | AMS-28.1-dgA | mAb (AMS-28.1) | mouse δ H chain of surface IgD (mδsIgD), domain Fc | B-cells | Yes | [476] | ||
| RTA | Hδa/1-dgA | mAb (Hδa/1) | mouse δ H chain of surface IgD (mδsIgD), domain Fc | B-cells | Yes | [476] | ||
| RTA | UCHL1-dgA | mAb (UCHL1) | CD45RO | HIV | Yes | [477-479] | ||
| RTA | My7/Fab' GAMIg.dgA | mAb (My7) / Fab' (GAM Ig) | CD13 | Myeloid leukemia | Yes | [465] | ||
| RTA | 1G10/Fab' GAMIg.dgA | mAb (My7) / Fab' (GAM Ig) | CD15 | Myeloid leukemia | Yes | [465] | ||
| RTA | rCD4-dgA | rCD4 (recombinant CD4) | HIVgp120 | HIV | Yes | [480] | ||
| RTA | Fib 75-ricin A chain | mAb (LICR-LOND Fib 75) | Bladder cancer antigen | Bladder cancer | Yes | Yes | [282-284] | |
| RTA | ITR | IgG (anti-Trypanosoma cruzi surface antigens) | Trypanosoma cruzi surface antigens | Trypanosoma cruzi | Yes | [288] | ||
| RTA | Anti-CD25/RTA | mAb (anti-CD25) | CD25 (IL-2 receptor) | Activated lymphocytes | Yes | [367, 407] | ||
| RTA | Anti-CD5/RTA | mAb (anti-CD5) | CD5 | T-lymphocytes | Yes | [366] | ||
| RTA | BerH2-RTA | mAb (Ber-H2) | CD30 | Lymphoblastoid, Hodgkin's lymphoma | Yes | [374, 481] | ||
| RTA | H65-RTA (CD5 Plus) (XomaZyme-CD5 Plus) | mAb (H65) | CD5 | GVHD, CTCL, CLL, rheumatoid arthritis, systemic lupus erythematosus (SLE), diabetes mellitus | Yes | Yes | Phase II | [482-487] |
| RTA | 454A12-rRA | mAb (454A12) | TfR | Breast cancer, leptomeningeal neoplasia | Yes | Yes | Phase I | [488, 489] |
| RTA | 260F9-rRTA | mAb (260F9) | 55 kDa breast cancer antigen (p55) | Breast cancer, ovarian cancer | Yes | Yes | Phase I | [490-492] |
| RTA | XMMME-001-RTA (XomaZyme-Mel) | mAb (XMMME-001) | Melanoma antigen (Proteoglycan) | Melanoma | Yes | Yes | Phase I/II | [493-498] |
| RTA | 791T/36-RTA (XomaZyme-791) | mAb (791T/36) | 72 kDa cancer antigen (72 kDa TAA) (p72) | Colorectal cancer | Yes | Yes | Phase I | [499, 500] |
| RTA | T101-RTA | mAb (T101) | CD5 | CLL | Yes | Yes | Phase I | [501-503] |
| RTA | T101-RTA | Fab (T101) | CD5 | T-cell leukemia | Yes | [504] | ||
| RTA | T101-RTA | F(ab')2 (T101) | CD5 | T-cell leukemia | Yes | [504] | ||
| RTA | MDX-RA (4197X-RA) | mAb (4197X) | Human lens epithelial antigen | Posterior capsule opacification (secondary cataract) | Yes | Phase III | [505-507] | |
| RTA | RTA-EGF | EGF | EGFR | Epidermoid carcinoma, EGFR+ cells | Yes | [84, 417, 508] | ||
| RTA | WT82-RTA | mAb (WT82) | CD8 | T-cell ALL | Yes | [509] | ||
| RTA | 2G5-RTA | mAb (2G5) | HLA-DR | Lymphoma, B cells, T cells, dendritic cells | Yes | [510] | ||
| RTA | CLL2m-RTA | mAb (CLL2m) | CLL2m antigen | ND, CLL | Yes | [511] | ||
| RTA | HAE3-RTA | mAb (HAE3) | Glycophorin-A | Erythromyeloblastoid leukemia | Yes | [512] | ||
| RTA | HAE9-RTA | mAb (HAE9) | Erythroid antigen | Erythromyeloblastoid leukemia | Yes | [512] | ||
| RTA | BMAC1/RTA | mAb (BMCA1) | CD45 | Allograft rejection | Yes | [369] | ||
| RTA | OX1/RTA | mAb (OX1) | rat CD45 | Allograft rejection | Yes | [369] | ||
| RTA | SN7-RTA | mAb (SN7) | SN7 B-cell antigen | B-cell leukemia, B-cell lymphoma | Yes | Yes | [513] | |
| RTA | HB21-RTA | mAb (HB21) (5E9) | TfR | Ovarian cancer, epidermoid carcinoma | Yes | [492] | ||
| RTA | R17217-rRTA | mAb (R17217) | Murine TfR | Lymphoma | Yes | Yes | [514] | |
| RTA | YE1/9.9-rRTA | mAb (YE1/9.9) | Murine TfR | Lymphoma | Yes | [514] | ||
| RTA | 0.5beta-RTA | mAb (0.5beta) | HIV gp120 | HIV | Yes | [515] | ||
| RTA | Anti-gp120-RTA | mAb (anti-gp120) | HIV gp120 | HIV | Yes | [516] | ||
| RTA | Anti-gp120-RTA | IgG (anti-gp120) | HIV gp120 | HIV | Yes | [517] | ||
| RTA | Anti-gp41-RTA | mAb (7B2) | HIV gp120 | HIV | Yes | Yes | [516, 518, 519] | |
| RTA | 171A-RTA | mAb (171A) | EpCAM | Colorectal cancer | Yes | [520] | ||
| RTA | MT151-RTA | mAb (MT151) | CD4 | ALL | Yes | [434] | ||
| RTA | MRK-RTA | mAb (MRK16) | P-glycoprotein | Kidney cancer | Yes | [521] | ||
| RTA | KM231-RTA | mAb (KM231) | Sialyl-Lea-antigen | Gastric cancer, colorectal cancer | Yes | Yes | [522] | |
| RTA | UCHT1 F(ab')2-RTA | F(ab')2 (UCHT1) | CD3ε | GVHD | Yes | Yes | [523] | |
| RTA | WT32-RTA | mAb (WT32) | CD3 | T-cell ALL | Yes | [524] | ||
| RTA | WT1-RTA | mAb (WT1) | CD7 | T-cell ALL, lymphoma | Yes | [524, 525] | ||
| RTA | 528-rRA | mAb (528) | EGFR | Lung cancer | Yes | Yes | [526] | |
| RTA | Anti-Tac-RTA | mAb (anti-CD25) | CD25 (IL-2 receptor) | T-cell leukemia, activated lymphocytes | Yes | [367, 527] | ||
| RTA | Tf-RTA | Transferrin | TfR | T-cell ALL, prostate cancer, malaria (Plasmodium falciparum) | Yes | [327, 528, 529] | ||
| RTA | Tf-KFT25-RTA | Transferrin | TfR | T-cell ALL | Yes | [528] | ||
| RTA | 520C9-RTA | mAb (520C9) | HER2 | Breast cancer | Yes | [530] | ||
| RTA | 741 F8-RTA | mAb (741 F8) | HER2 | Breast cancer | Yes | [530] | ||
| RTA | 454C11-RTA | mAb (454C11) | HER2 | Breast cancer | Yes | [530] | ||
| RTA | STI-RTA | mAb (STI) | CD5 | T-cell ALL | Yes | [531] | ||
| RTA | RTA-9.2.27 | mAb (9.2.27) | Melanoma-associated antigen (p250) | Melanoma | Yes | Yes | [280] | |
| RTA | BrE-3-RTA | mAb (BrE-3) | Mucin, MUC1 | SCLC | Yes | [532] | ||
| RTA | C242-RTA (ICI D0490) | mAb (C242) | Mucin | Colorectal cancer | Yes | Yes | [533] | |
| RTA | 84.1c-RTA | mAb (84.1c) | mIgE | Allergies | Yes | Yes | [534] | |
| RTA | HRS-3.dgA | mAb (HRS-3) | CD30 | Hodgkin's lymphoma, myeloma | Yes | [465, 535] | ||
| RTA | HRS-3Fab'.dgA | Fab' (HRS-3) | CD30 | Hodgkin's lymphoma | Yes | [535] | ||
| RTA | HRS-4.dgA | mAb (HRS-4) | CD30 | Hodgkin's lymphoma | Yes | [535] | ||
| RTA | HRS-4Fab'.dgA | Fab' (HRS-4) | CD30 | Hodgkin's lymphoma | Yes | [535] | ||
| RTA | HRS-1.dgA | mAb (HRS-1) | CD30 | Hodgkin's lymphoma | Yes | [535] | ||
| RTA | 90Y-C110-RTA | mAb (C110) | Carcinoembryonic antigen (CEA) | Colon cancer | Yes | Yes | [536] | |
| RTA | C19-RTA | mAb (C19) | Carcinoembryonic antigen (CEA) | Colorectal cancer | Yes | [537] | ||
| RTA | M6-RTA | mAb (M6) | L2C IgM idiotype | B-cell leukemia | Yes | Yes | [409] | |
| RTA | 38.13-RTA | mAb (38.13) | TH ceramide (Pk antigen) | Burkitt's lymphoma | Yes | [324] | ||
| RTA | Fab'-anti-L3T4-A | Fab' (anti-L3T4) | Murine T-cell antigen (limpet hemocyanin-specific T-helper lymphocytes) | Lymphoma | Yes | [538] | ||
| RTA | 486P-RTA | mAb (486P 3-12-1) | Bladder cancer antigen | Bladder cancer | Yes | [539] | ||
| RTA | RFT11-A | mAb (RFT11) | CD2 | T-cell ALL | Yes | [540] | ||
| RTA | 35.1-A | mAb (35.1) | CD2 | T-cell ALL | Yes | [464, 540] | ||
| RTA | 9.6-A | mAb (9.6) | CD2 | T-cell ALL | Yes | [464, 540] | ||
| RTA | 10.2-A | mAb (10.2) | CD5 | T cells | Yes | [464] | ||
| RTA | 452-D9-RTA | mAb (452-D9) | gp74 | c-Ha-ras expression tumors, Kirsten sarcoma | Yes | Yes | [541, 542] | |
| RTA | Thyroglobulin-RTA | Thyroglobulin | Ig (anti-thyroglobulin) | Thyroiditis | Yes | [543] | ||
| RTA | 96.5-RTA | mAb (96.5) | p97 | Melanoma | Yes | [544] | ||
| RTA | SN5d-RTA | mAb (SN5d) | CD10 (CALLA) | Pre-B-cell ALL | Yes | Yes | [545] | |
| RTA | SN5-RTA | mAb (SN5) | CD10 (CALLA) | Pre-B-cell ALL | Yes | Yes | [545] | |
| RTA | Anti-CALLA-RTA | mAb (anti-CALLA) | CD10 (CALLA) | Burkitt's lymphoma, (pre-B-cell ALL) | Yes | [546] | ||
| RTA | Anti-CALLA-RTA | Fab' (anti-CALLA) | CD10 (CALLA) | Burkitt's lymphoma, (pre-B-cell ALL) | Yes | [546] | ||
| RTA | Anti-GE2-RTA | mAb (anti-GE2) | GE2 | Glioma | Yes | [410] | ||
| RTA | D1/12-RTA | mAb (D1/12) | HLA-DR | Glioma | Yes | [410] | ||
| RTA | AR3-RTA | mAb (AR3) | CAR-3 | Gastric cancer | Yes | [411] | ||
| RTA | 8C-RTA | mAb (8C) | Ovarian cancer antigen | Ovarian cancer | Yes | Yes | [547] | |
| RTA | M2A-RTA | mAb (M2A) | Ovarian cancer antigen | Ovarian cancer | Yes | Yes | [547] | |
| RTA | Anti-vasopressin-RTA | mAb (anti-vasopressin) | Vasopressin | Pituitary cancer | Yes | Yes | [548] | |
| RTA | Cluster 2 Mab-Fab'-Anti-Mouse/RAT-RTA | mAb (Cluster 2) | Cluster 2 antigen-SCLC | SCLC | Yes | [549] | ||
| RTA | SOKT1-RTA | mAb (SOKT1) | T-cell antigen | T cells | Yes | [550] | ||
| RTA | MGb2-RTA | mAb (MGb2) | Gastric antigen | Gastric cancer | Yes | [551] | ||
| RTA | MG11-RTA | mAb (MG11) | Gastric antigen | Gastric cancer | Yes | [551] | ||
| RTA | MoAb-16-RTA | mAb (16) | Oncofetal antigen | Leukemia | Yes | Yes | [368, 552] | |
| RTA | Anti-laryngeal cancer-RTA | mAb (anti-laryngeal cancer) | Laryngeal cancer antigen | Laryngeal cancer | Yes | [553, 554] | ||
| RTA | 317G5-RTA | mAb (317G5) | 42 kDa glycoprotein (p42) | Breast cancer | Yes | [555] | ||
| RTA | SEN36-RTA | mAb (SEN36) | CD56 (N-CAM) | SCLC | Yes | [556] | ||
| RTA | Anti-mu-RTA | mAb (anti-mu) | Mu chain of IgM | Myeloma | Yes | [557] | ||
| RTA | SEN7-bR | mAb (SEN7) | CD56 (N-CAM) | SCLC | Yes | [558] | ||
| RTA | Anti-CRF-RTA | mAb (anti-CRF) | CRF (corticotropin-releasing factor) | Immunolesioning (CRF neurons within the paraventricular nucleus of the hypothalamus) | Yes | [559] | ||
| RTA | Anti-asialo-GM2-RTA | mAb (anti-asialo-GM2) | Asialo-GM2 | Lymphoma | Yes | [560] | ||
| RTA | Anti-H-2d-RTA | mAb (anti-H-2d) | H-2d | Lymphoma | Yes | [560] | ||
| RTA | V beta 6-specific immunotoxin (VIT6) | mAb (anti-V beta 6-specific) | V beta-associated antigen receptor | Myasthenia gravis | Yes | [561] | ||
| RTA | schM21-ricin A | scFv (schM21) | Astrocytoma- and medulloblastoma-associated antigen | Medulloblastoma | Yes | [562] | ||
| RTA | ONS-M21-RTA (ORA) | mAb (ONS-M21) | Astrocytoma- and medulloblastoma-associated antigen | Medulloblastoma | Yes | [563] | ||
| RTA | Anti-VIP-RTA | mAb (anti-VIP) | Vasoactive intestinal polypeptide (VIP) | Pheochromocytoma, immunolesioning (neurons within the SCN) (suprachiasmatic nucleus of the hypothalamus) | Yes | Yes | [564] | |
| RTA | Anti-Thy 1.2-RTA | IgG (anti-Thy 1.2) | CD90.2 (Thy 1.2) | Leukemia | Yes | Yes | [565] | |
| RTA | IgE-ricin A-chain | mAb (IR162) | IgE Fc receptor | Allergies, basophil leukemia | Yes | Yes | [566, 567] | |
| RTA | OX-40-ricin A | mAb (anti-OX-40) | OX-40 | Autoimmune encephalomyelitis (EAE) | Yes | Yes | [568] | |
| RTA | SWA20-RTA | mAb (SWA20) | CD24 | SCLC | Yes | [467] | ||
| RTA | Anti-T. cruzi-RTA | IgG (anti-Trypanosoma cruzi surface antigens) | Trypanosoma cruzi surface antigens | Trypanosoma cruzi | Yes | Yes | [288] | |
| RTA | UCHT1/F(ab')2-ricin A chain | mAb (UCHT1) / F(ab')2 (anti-IgG) | CD3 | T-cell lymphoma | Yes | [303] | ||
| RTA | RTA-NIM-R7 | mAb (NIM-R7) | p58 | Lymphoma | Yes | [569] | ||
| Saporin | Anti-Thy 1.1 (F(ab')2)-saporin | F(ab')2 (anti-Thy 1.1) (OX7) | CD90.1 (Thy 1.1) | AKR-A lymphoma | Yes | Yes | [570] | |
| Saporin | Anti-Thy 1.1 (mAb)-saporin | mAb (anti-Thy 1.1) (OX7) | CD90.1 (Thy 1.1) | AKR-A lymphoma | Yes | Yes | [570] | |
| Saporin | 192 IgG-saporin (192-IgG-SAP) (IgG-192) | mAb (192) | Rat nerve growth factor receptor (p75NTR) | Immunolesioning (cholinergic basal forebrain neurons), Alzheimer's disease | Yes | Yes | [571-574] | |
| Saporin | OM124-saporin | mAb (OM124) | CD22 | Burkitt's B-cell lymphoma, Epstein-Barr virus-infected B lymphoblastoid cells | Yes | Yes | [370] | |
| Saporin | M24-saporin (anti-CD80/saporin) | mAb (M24) | CD80 | Hodgkin's lymphoma, Burkitt's lymphoma | Yes | [295] | ||
| Saporin | 1G10-saporin (anti-CD86/saporin) | mAb (1G10) | CD86 | Hodgkin's lymphoma, Burkitt's lymphoma | Yes | [295] | ||
| Saporin | M24-saporin / 1G10-saporin | mAb (M24) / mAb (1G10) | CD80 + CD86 | Burkitt's lymphoma, Hodgkin's lymphoma | Yes | [295] | ||
| Saporin | OKT11-saporin | mAb (OKT11) | CD2 | T-CLL | Yes | [575, 576] | ||
| Saporin | 7A10C9-saporin | mAb (7A10C9) | CD2 | T-CLL | Yes | [575] | ||
| Saporin | OKT1-saporin | OKT1 | CD5 | T-lymphocytes, B-CLL | Yes | Yes | [577-579] | |
| Saporin | BsAb (HB2 x anti-saporin)/(OKT10 x anti-saporin)/saporin | Bispecific F(ab')2 (HB2 x anti-saporin)/(OKT10 x anti-saporin) | CD7 + CD38 | T-ALL | Yes | [580] | ||
| Saporin | BsAb (HB2 x anti-saporin)/saporin | Bispecific F(ab')2 (HB2 x anti-saporin) | CD7 | T-ALL | Yes | [581] | ||
| Saporin | BsAb (OKT10 x anti-saporin)/saporin | Bispecific F(ab')2 (OKT10 x anti-saporin) | CD38 | T-ALL | Yes | [580] | ||
| Saporin | HB2-saporin | mAb (HB2) | CD7 | Lymphoma, T-ALL | Yes | Yes | [582-584] | |
| Saporin | BU12-saporin | mAb (BU12) | CD19 | B-LL, Burkitt's lymphoma | Yes | Yes | [585-587] | |
| Saporin | Rituximab/saporin-S6 | mAb (rituximab) | CD20 | NHL | Yes | [588] | ||
| Saporin | BsAb (4KB128 x anti-saporin)/saporin | Bispecific F(ab')2 (4KB128 x anti-saporin) | CD22 | Burkitt's lymphoma | Yes | [589] | ||
| Saporin | BsAb (HD37 x anti-saporin)/saporin | Bispecific F(ab')2 (4KB128 x anti-saporin) | CD19 | Burkitt's lymphoma | Yes | [589] | ||
| Saporin | BsAb (MB-1 x anti-saporin)/saporin | Bispecific F(ab')2 (4KB128 x anti-saporin) | CD37 | Burkitt's lymphoma | Yes | [589] | ||
| Saporin | BsAb (4KB128 x anti-saporin)/(RFB9 x anti-saporin)/saporin | Bispecific F(ab')2 (4KB128 x anti-saporin)/(RFB9 x anti-saporin) | CD22 | Lymphoma, CLL | Yes | Yes | Phase I | [590] |
| Saporin | BsAb (4KB128 x anti-saporin)/(HD6 x anti-saporin)/saporin | Bispecific F(ab')2 (4KB128 x anti-saporin)/(HD6 x anti-saporin) | CD22 | B-cell lymphoma | Yes | Yes | Phase I | [591] |
| Saporin | IB4/saporin-S6 | mAb (IB4) | CD38 (alpha-D-Galactopyranoside residues) | NHL | Yes | [592] | ||
| Saporin | Anti-B7-1-saporin | mAb (B7-24) | CD80 | Burkitt's lymphoma, Hodgkin's lymphoma | Yes | [593] | ||
| Saporin | Anti-CTLA-4 (83)-saporin (83-saporin) | scFv (83) | CD152 (Cytotoxic T-lymphocyte antigen-4, CTLA-4) | Transplantation tolerance, leukemia, EBV-positive B-cell lymphoblastoid | Yes | Yes | [594-596] | |
| Saporin | Anti-CTLA-4 (40)-saporin (40-saporin) | scFv (40) | CD152 (Cytotoxic T-lymphocyte antigen-4, CTLA-4) | Transplantation tolerance, EBV-positive B-cell lymphoblastoid | Yes | Yes | [594, 595] | |
| Saporin | Anti-CTLA-4 (67)-saporin (67-saporin) | scFv (67) | CD152 (Cytotoxic T-lymphocyte antigen-4, CTLA-4) | Transplantation tolerance, leukemia | Yes | [596] | ||
| Saporin | ATG-saporin-S6 | Antithymocyte globulin (ATG) | Thymocyte | Lymphoma, leukemia | Yes | [597] | ||
| Saporin | HD6-saporin | mAb (HD6) | CD22 | Lymphoma, B-CLL | Yes | [598] | ||
| Saporin | HD39-saporin | mAb (HD39) | CD22 | Lymphoma, B-CLL | Yes | [598] | ||
| Saporin | HD37-saporin | mAb (HD37) | CD19 | B-cell lymphoma | Yes | [598] | ||
| Saporin | Saporin-EGF (SE) | EGF | EGFR | Breast cancer, sarcoma, adenocarcinoma, cervical cancer | Yes | Yes | [599-602] | |
| Saporin | SA2E | EGF | EGFR | Breast cancer | Yes | Yes | [599-601] | |
| Saporin | FGF-SAP | FGF | FGFR | Melanoma, teratocarcinoma, neuroblastoma | Yes | Yes | [603] | |
| Saporin | FGF2-SAP | FGF-2 | FGFR | Bladder cancer | Yes | [604] | ||
| Saporin | bFGF-saporin | bFGF | bFGFR | Prostate cancer | Yes | Yes | [605] | |
| Saporin | ch25A11-Sap | mAb (ch25A11) | CUB domain-containing protein 1 (CDCP1) | Prostate cancer | Yes | Yes | [606] | |
| Saporin | hJ591-saporin | mAb (hj591) | Prostate-specific membrane antigen (PSMA) | Prostate cancer | Yes | Yes | [607] | |
| Saporin | Ep2-saporin | mAb (Ep2) | Proteoglycan, p250 | Melanoma | Yes | [608] | ||
| Saporin | ML30-saporin | mAb (ML30) | Heat shock protein 65 kDa (HSP65) | Leukemic monocyte lymphoma, pancreatic cancer | Yes | Yes | [609, 610] | |
| Saporin | 48-127/saporin-S6 | mAb (48-127) | gp54 | Bladder cancer | Yes | [379] | ||
| Saporin | Anti-ALCAM/CD166 scFv-saporin | scFv (I/F8) | CD166 (activated leukocyte cell adhesion molecule, ALCAM) | SCLC, ovarian cancer | Yes | [611] | ||
| Saporin | 7E4B11-saporin | mAb (7E4B11) | RPTPβ | Astrocytic tumor, glioblastoma | Yes | Yes | [612] | |
| Saporin | Ber-H2-Saporin | mAb (Ber-H2) | CD30 | Hodgkin's lymphoma, anaplastic large-cell lymphoma(ALCL) | Yes | Yes | Phase I | [374, 613-616] |
| Saporin | Sap-ac-LDL | Acetylated LDL | Rat scavenger receptor | Immunolesioning (microglia) | Yes | [617, 618] | ||
| Saporin | Anti-basigin-2-saporin | mAb (anti-basigin-2) | Human basigin-2 (CD147) (EMMPRIN) | Ovarian cancer | Yes | [619] | ||
| Saporin | M290-SAP | mAb (M290) | CD103 | Organ allograft rejection and GVHD | Yes | Yes | [620] | |
| Saporin | Anti-ChAT IgG-saporin | mAb (anti-ChAT) | Choline acetyltransferase (ChAT) | Parkinson's and schizophrenia | Yes | [621-623] | ||
| Saporin | Anti-DAT-saporin | mAb (anti-DAT) | Dopamine transporter (DAT) | Immunolesioning (dopaminergic neurons) | Yes | [624] | ||
| Saporin | Anti-DBH-saporin | mAb (anti-DBH) | Dopamine beta-hydroxylase (DBH) | Immunolesioning (noradrenergic neurons) | Yes | [625-627] | ||
| Saporin | Anti-SERT-SAP | mAb (anti-SERT) | Serotonin reuptake transporter (SERT) | Immunolesioning (serotonergic neurons) | Yes | Yes | [628] | |
| Saporin | Bombesin-SAP | Bombesin | Gastrin-releasing peptide receptor (GRPR) | Immunolesioning (GRPR+ neurons) | Yes | Yes | [629, 630] | |
| Saporin | CCK-saporin | CCK (cholecystokinin) | Cholecystokinin type 2 receptor (CCK2) | Immunolesioning (CCK+ neurons) | Yes | [631] | ||
| Saporin | CRF-SAP | CRF (corticotropin-releasing factor) | CRF receptor | Immunolesioning (CRFR+ cells) | Yes | Yes | [632, 633] | |
| Saporin | CTB-SAP | CTB (cholera toxin B-subunit) | GM1 ganglioside | Immunolesioning (paraplegia) | Yes | [634] | ||
| Saporin | Dermorphin-saporin (MOR-SAP) | Dermorphin | Mu opioid receptor (MOR) | Immunolesioning (MOR+ neurons) | Yes | [631] | ||
| Saporin | Galanin-saporin (Gal-sap) | Galanin | Galanin-1 receptor (GalR1) | Immunolesioning (GalR1+ neurons) | Yes | [635] | ||
| Saporin | GAT1-saporin | IgG (GAT1) | GABA-transporter-1 | Immunolesioning (MSDB neurons), Alzheimer's disease | Yes | [636] | ||
| Saporin | Lep-SAP | Leptin | Leptin receptor | Immunolesioning (leptin receptor+ neuons) | Yes | [637, 638] | ||
| Saporin | Anti-Mac-1-SAP | mAb (anti-Mac-1) | CD11b (Mac-1) | Immunolesioning (Mac-1+ neuons, microglia) | Yes | Yes | [639-642] | |
| Saporin | ME20.4 IgG-saporin | mAb (ME20.4) | Primate p75 low-affinity neurotrophin receptor (p75NTR) | Immunolesioning (p75NTR+ neuons) | Yes | [643, 644] | ||
| Saporin | UF008/SAP | IgG (UF008) | Melanopsin | Immunolesioning (intrinsically photosensitive retinal ganglion cells, ipRGCs) | Yes | Yes | [645, 646] | |
| Saporin | NK3-SAP | Neurokinin-3 (NK3) | Neurokinin-3 receptor (NK3R) | Immunolesioning (NK3R+ neuons) | Yes | [647] | ||
| Saporin | NPY-SAP | Neuropeptide Y (NPY) | Neuropeptide Y receptor (NPYR) | Immunolesioning (NPYR+ neuons) | Yes | [648, 649] | ||
| Saporin | OXY-SAP | Oxytocin | Oxytocin receptors (OXYR) | Immunolesioning (OXYR+ neuons) | Yes | Yes | [650] | |
| Saporin | Substance P-saporin | Substance P | Neurokinin-1 receptor (NK1R) (Substance P receptor) | Immunolesioning (NK1R+ neurons), hyperalgesia | Yes | [651-653] | ||
| Saporin | Hypocretin-saporin | Hypocretin (orexin) | Hypocretin-2 receptor | Narcolepsy (parvalbumin and cholinergic neurons) | Yes | [654] | ||
| Saporin | TEC-T4-saporin | mAb (TEC-T4) | CD4 | T cells | Yes | [655] | ||
| Saporin | MB-1 x anti-sap-1/saporin | Bispecific mAb (MB-1 x anti-sap-1) | CD37 | Burkitt's lymphoma | Yes | [589] | ||
| Saporin | OKT10-saporin | mAb (OKT10) | CD38 | T-cell ALL, lymphocytes, macrophages | Yes | Yes | [584] | |
| Saporin | Campath-1-saporin | mAb (Campath-1) | CD52 | GVHD, myeloid cells | Yes | Yes | [656] | |
| Saporin | TEC IgM-SAP | mAb (TEC IgM) | Immunoglobulin heavy chain | Burkitt’s lymphoma | Yes | [657] | ||
| Saporin | 8A-saporin 6 | mAb (8A) | 8A plasma cell-associated antigens | Multiple myeloma, Burkitt’s lymphoma | Yes | [658] | ||
| Saporin | 62B1-saporin | mAb (62B1) | 62B1 plasma cell-associated antigens | Multiple myeloma, Burkitt’s lymphoma | Yes | [658] | ||
| Saporin | 3BIT (BU12-saporin / OKT10-saporin + 4KB128-saporin) | mAb (BU12) / (OKT10) / (4KB128) | CD19 + CD22 + CD38 | Burkitt’s lymphoma | Yes | Yes | [659] | |
| Saporin | BU12-saporin / OKT10-saporin | mAb (BU12) / (OKT10) | CD19 + CD38 | Burkitt’s lymphoma | Yes | Yes | [586] | |
| Saporin | HB2-saporin / OKT10-saporin | mAb (HB2) / (OKT10) | CD7 + CD38 | T-cell ALL | Yes | Yes | [584] | |
| Saporin | B3/25-SO6 | mAb (B3/25) | TfR | Leukemia | Yes | [660] | ||
| Saporin | LAM3/saporin | mAb (LAM3) | M5b leukemia antigen | Acute non-lymphoid leukemia (ANLL) | Yes | [610, 661] | ||
| Saporin | Tf-saporin | Transferrin | TfR | Prostate cancer | Yes | [529] | ||
| Saporin | uPA-SAP | uPAcs (urokinase-type plasminogen activator) | Urokinase receptor | Lymphoma | Yes | [662] | ||
| Saporin | 11A8-saporin | mAb (11A8) | bFGFR | Ovarian cancer | Yes | Yes | [663] | |
| Saporin | Anti-CD8-saporin | mAb (anti-CD8) | CD8 | T-cell lymphoma | Yes | [655] | ||
| Saporin | HBEGF-saporin | HB-EGF | EGFR | Breast cancer, bladder cancer, melanoma, leukemia, colon cancer, renal cancer, ovarian cancer, prostate cancer, non-small cell lung cancer (NSCLC), brain cancer | Yes | [664] | ||
| Saporin | HBEGF-L22-saporin | HB-EGF | EGFR | Breast cancer, bladder cancer, melanoma, leukemia, colon cancer, renal cancer, ovarian cancer, prostate cancer, non-small cell lung cancer (NSCLC), brain cancer | Yes | Yes | [664] | |
| Saporin | B-B10-saporin | mAb (B-B10) | CD25 (IL-2 receptor) | GVHD | Yes | [665] | ||
| Saporin | W6/800E6-SAP | mAb (W6/800E6) | HER2 | Breast cancer | Yes | [666] | ||
| Saporin | W6/900H1-SAP | mAb (W6/900H1) | HER2 | Breast cancer | Yes | [666] | ||
| Saporin | H2-Dd-saporin | H2-Dd MHC class I tetramer | T-cell receptor (TCR) | diabetes mellitus, CD8+ T cells | Yes | [667] | ||
| Saporin | 2F8-saporin | mAb (2F8) | CD163 (SR-A) | Ovarian cancer | Yes | Yes | [668] | |
| Saporin | Insulin-saporin (saporin insulin complex, SIC) | Insulin | Insulin receptor | Ovarian cancer, hepatocellular carcinoma | Yes | [669] | ||
| Saporin | B-B2-saporin | mAb (BB2) | Myeloma antigen | Multiple myeloma | Yes | [670] | ||
| Saporin | B-B4-saporin | mAb (BB4) | Myeloma antigen | Multiple myeloma | Yes | [670] | ||
| Saporin | Anti-epithelial antigen-saporin 6 | mAb (anti-epithelial antigen) | Epithelial antigen | Colon cancer, epidermoid carcinoma | Yes | [302] | ||
| Saporin | Anti-SA-1-saporin | mAb (anti-SA-1) | mAb (SA-1) (16/6 idiotype binding to DNA) | Systemic lupus erythematosus (SLE) | Yes | Yes | [671] | |
| Saporin | Anti-Id-saporin | mAb (anti-Id) | mAb (Anti-Id) (anti-lymphoma idiotype) | B-cell leukemia | Yes | Yes | [672] | |
| Saporin | HB6-1 x anti-sap-1/saporin | Bispecific mAb (HB6-1 x anti-sap-1) | κ-chain | Burkitt's lymphoma | Yes | [589] | ||
| Saporin | M15-8 x anti-sap-1/saporin | Bispecific mAb (M15-8 x anti-sap-1) | µ-chain | Burkitt's lymphoma | Yes | [589] | ||
| Saporin | RFB-9 x anti-sap-1/saporin | Bispecific mAb (RFB-9 x anti-sap-1) | CD19 | Burkitt's lymphoma | Yes | [589] | ||
| Saporin | WR17 x anti-sap-1/saporin | Bispecific mAb (WR17 x anti-sap-1) | CD37 | Burkitt's lymphoma | Yes | [589] | ||
| Saporin | LAM7/saporin | mAb (LAM7) | M5b leukemia antigen | Acute non-lymphoid leukemia (ANLL) | Yes | [610, 661] | ||
| Saporin | 62B8-saporin 6 | mAb (62B8) | 62B8 myeloma antigen | Multiple myeloma | Yes | [658] | ||
| Saporin | F(ab')2-saporin/UCHT1 | F(ab')2 (anti-IgG) / mAb (UCHT1) | CD3 | T-cell lymphoma | Yes | [303] | ||
| Saporin | F(ab')2-saporin/anti-CD2 | F(ab')2 (anti-IgG) / mAb (anti-CD2) | CD2 | T-cell lymphoma | Yes | [303] | ||
| Saporin | F(ab')2-saporin/anti-CD5 | F(ab')2 (anti-IgG) / mAb (anti-CD5) | CD5 | T-cell lymphoma | Yes | [303] | ||
| Saporin | F(ab')2-saporin/C11 | F(ab')2 (anti-IgG) / mAb (C11) | CD45 | Hodgkin's lymphoma | Yes | [303] | ||
| Saporin | F(ab')2-saporin/TEC-T4 | F(ab')2 (anti-IgG) / mAb (TEC-T4) | CD4 | T-cell lymphoma | Yes | [303] | ||
| Saporin | F(ab')2-saporin/HSR-3 | F(ab')2 (anti-IgG) / mAb (HSR-3) | CD30 | Hodgkin's lymphoma | Yes | [303] | ||
| Saporin | F(ab')2-saporin/8A | F(ab')2 (anti-IgG) / mAb (8A) | 8A myeloma antigen | Burkitt lymphoma, multiple myeloma | Yes | [303] | ||
| Saporin | F(ab')2-saporin/62B1 | F(ab')2 (anti-IgG) / mAb (62B1) | 62B1 myeloma antigen | Multiple myeloma | Yes | [303] | ||
| Saporin | PlGF-2-saporin | Placental growth factor-2 (PlGF-2) | PlGF-2 receptor | Tumor neovascularization | Yes | [673] | ||
| Saporin | ATF-saporin | ATF (amino-terminal fragment of human urokinase) | Urokinase receptor | Metastasis | Yes | [674] | ||
| Saporin | Cetuximab-saporin | mAb (cetuximab) | EGFR | Colorectal cancer, prostate cancer, epidermoid carcinoma, breast cancer | Yes | [675, 676] | ||
| Saporin | Trastuzumab-saporin | mAb (trastuzumab) | HER2 | Breast cancer | Yes | [676, 677] | ||
| Saporin | 2H8/anti-GAM IgG-saporin | mAb (2H8) / IgG (anti-GAM IgG) | Tomoregulin | Prostate cancer | Yes | [678] | ||
| Saporin | By114/anti-IgG-saporin | mAb (By114) / IgG (anti-IgG) | Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) | Pancreatic cancer | Yes | Yes | [679] | |
| Saporin | 6-22 IgG/anti-GAH IgG-saporin | mAb (6-22 IgG) / IgG (anti-GAH IgG) | Human aspartyl (asparaginyl) β-hydroxylase (HAAH) | Hepatocellular carcinoma | Yes | [680] | ||
| Saporin | Anti-endosialin/anti-IgG-saporin | mAb (anti-endosialin) / IgG (anti-IgG) | Endosialin (CD248, tumor endothelial marker 1, TEM1) | Ewing's sarcoma, neuroblastoma | Yes | [681] | ||
| Saporin | Anti-TCblR-saporin | mAb (anti-TCblR) | CD320 (transcobalamin receptor, TCblR) | CML, colon cancer | Yes | [682] | ||
| Saporin | AF334-saporin | mAb (AF334) | Tumor endothelial marker 8 (TEM8) | Tumor neovascularization | Yes | [683] | ||
| Saporin | MRK16/anti-IgG-saporin | mAb (MRK16) / IgG (anti-IgG) | 170 kDa glycoprotein (gp170) | Colon cancer | Yes | [684] | ||
| Trichokirin | AT15E-TKR (AT15E-Trichokirin) | mAb (anti-Thy 1.2) (AT15E) | CD90.2 (Thy 1.2) | Leukemia | Yes | Yes | [270] | |
| Trichokirin | F(ab')2-trichokirin/UCHT1 | F(ab')2 (anti-IgG) / mAb (UCHT1) | CD3 | T-cell lymphoma | Yes | [303] | ||
| Trichosanthin | TCS-Hepama-1 (Hepama-1-trichosanthin) | mAb (Hepama-1) | Hepatoma-associated antigen 43 kDa glycoprotein | Hepatoma | Yes | Yes | [685, 686] | |
| Trichosanthin | p75-TCS (anti-p75-anti-mouse IgG-trichosanthin) | mAb (192) / IgG (anti-mouse) | Rat nerve growth factor (NGF) receptor (p75 receptor) (p75NTR) | Immunolesioning (cholinergic basal forebrain neurons) | Yes | [574] | ||
| Trichosanthin | CMU15—TCS | mAb (CMU15A) | Lung cancer antigen | Lung cancer | Yes | Yes | [687, 688] | |
| Trichosanthin | TCS-Ng76 | mAb (Ng76) | Melanoma antigen | Melanoma | Yes | [689] | ||
| Trichosanthin | EGF-TCS | EGF | EGFR | Hepatocellular carcinoma | Yes | Yes | [690, 691] | |
| Trichosanthin | EGF-TCSredlk | EGF | EGFR | Hepatocellular carcinoma | Yes | Yes | [692] |